FDA has approved Pylarify (piflufolastat F 18) – a drug for positron emission tomography (PET) imaging of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate …

May 1, 2020 · F18-PSMA is a novel PSMA ligand which progressively replaces the previously introduced Ga68-PSMA. The purpose of this study was to assess the frequency of benign F18 …

18 F-PSMA-1007 performs at least comparably to 68 Ga-PSMA-11, but its longer half-life combined with its superior energy characteristics and non-urinary excretion overcomes some …

Nearly all prostate cancers express prostate-specific membrane antigen (PSMA) and 18 F-DCFPyL (piflufolastat F 18) is a new FDA-approved positron emission tomography (PET) …

May 30, 2023 · The FDA has approved flotufolastat F 18 (formerly 18 F-rhPSMA-7.3; trade name, Posluma) for PET imaging of PSMA-positive lesions in men with prostate cancer with …

In comparison to other PSMA-targeting PET-tracers, 18 F-PSMA-1007 has reduced urinary clearance enabling excellent assessment of the prostate. Similar to 18 F-DCFPyL and with …

18 F-PSMA-1007 PET/CT demonstrated a high detection rate for patients with BCR after radical prostatectomy. 18 F-PSMA-1007 PET/CT could improve patient management by correctly …

Sep 7, 2023 · Shared insight into FDA-approved PSMA PET imaging tracers, highlighting similarities and differences between gallium 68 and fluorine 18 compounds.

Dec 1, 2020 · Prostate-specific membrane antigen (PSMA)-based positron-emission tomography (PET)-computed tomography (CT) has shown great promise in prostate cancer imaging. This …

Fluorine-18 (18 F)-labelled prostate-specific membrane antigen (PSMA) offers several advantages over gallium-68 (68 Ga) in terms of costs, yield, transport/distribution, and image …